B Alipoor1, S Nikouei2, F Rezaeinejad3, S-N Malakooti-Dehkordi4, Z Sabati5, H Ghasemi6. 1. Department of Laboratory Sciences, Faculty of Paramedicine, Yasuj University of Medical Sciences, Yasuj, Iran. 2. Student Research Committee, Yasuj University of Medical Sciences, Yasuj, Iran. 3. Department of Biochemistry, Faculty of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran. 4. Abadan Faculty of Medical Sciences, Abadan, Iran. 5. MSc student of Hematology, Student Research Committee, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. 6. Abadan Faculty of Medical Sciences, Abadan, Iran. clinicalbiochem.1365@gmail.com.
Abstract
BACKGROUND: It has been suggested that dysregulation of long non-coding RNAs (lncRNAs) could be associated with the incidence and development of metabolic disorders. AIM: Accordingly, this narrative review described the molecular mechanisms of lncRNAs in the development of metabolic diseases including insulin resistance, diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), cirrhosis, and coronary artery diseases (CAD). Furthermore, we investigated the up-to-date findings on the association of deregulated lncRNAs in the metabolic disorders, and potential use of lncRNAs as biomarkers and therapeutic targets. CONCLUSION: LncRNAs/miRNA/regulatory proteins axis plays a crucial role in progression of metabolic disorders and may be used in development of therapeutic and diagnostic approaches.
BACKGROUND: It has been suggested that dysregulation of long non-coding RNAs (lncRNAs) could be associated with the incidence and development of metabolic disorders. AIM: Accordingly, this narrative review described the molecular mechanisms of lncRNAs in the development of metabolic diseases including insulin resistance, diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), cirrhosis, and coronary artery diseases (CAD). Furthermore, we investigated the up-to-date findings on the association of deregulated lncRNAs in the metabolic disorders, and potential use of lncRNAs as biomarkers and therapeutic targets. CONCLUSION: LncRNAs/miRNA/regulatory proteins axis plays a crucial role in progression of metabolic disorders and may be used in development of therapeutic and diagnostic approaches.
Authors: Vidisha Tripathi; Jonathan D Ellis; Zhen Shen; David Y Song; Qun Pan; Andrew T Watt; Susan M Freier; C Frank Bennett; Alok Sharma; Paula A Bubulya; Benjamin J Blencowe; Supriya G Prasanth; Kannanganattu V Prasanth Journal: Mol Cell Date: 2010-09-24 Impact factor: 17.970
Authors: Ezgi Hacisuleyman; Loyal A Goff; Cole Trapnell; Adam Williams; Jorge Henao-Mejia; Lei Sun; Patrick McClanahan; David G Hendrickson; Martin Sauvageau; David R Kelley; Michael Morse; Jesse Engreitz; Eric S Lander; Mitch Guttman; Harvey F Lodish; Richard Flavell; Arjun Raj; John L Rinn Journal: Nat Struct Mol Biol Date: 2014-01-26 Impact factor: 15.369
Authors: Martin Hemberg; Jesse M Gray; Nicole Cloonan; Scott Kuersten; Sean Grimmond; Michael E Greenberg; Gabriel Kreiman Journal: Nucleic Acids Res Date: 2012-06-08 Impact factor: 16.971
Authors: Eduardo López-Urrutia; Lilia P Bustamante Montes; Diego Ladrón de Guevara Cervantes; Carlos Pérez-Plasencia; Alma D Campos-Parra Journal: Front Oncol Date: 2019-07-25 Impact factor: 6.244